Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. (Q39609930)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Scott Ayton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

David I Finkelstein

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Peter J. Crack

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Juliet M Taylor

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Bevan S Main

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Moses Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Kate M Brody

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

David Steer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

1 reference

12 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

1590-1604

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

Interferon-induced Parkinsonism in a patient with chronic hepatitis C.

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Epidemiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

The interferons and their receptors--distribution and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Ischemic Preconditioning in White Matter: Magnitude and Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

IRF-7 is the master regulator of type-I interferon-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

The IRF family transcription factors at the interface of innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

IFN regulatory factor 8 is a key constitutive determinant of the morphological and molecular properties of microglia in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

LRRK2 inhibition attenuates microglial inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

IRF7: activation, regulation, modification and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Interferons in the central nervous system: a few instruments play many tunes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Immunological features of alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

The MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Blocking Monoclonal Antibodies Specific for Mouse IFN-α/β Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

7 January 2021

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

7 January 2021

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

7 January 2021

Interferon regulatory factor 7 participates in the M1-like microglial polarization switch

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

7 January 2021

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.23028

7 January 2021

Identifiers

DOI

10.1002/GLIA.23028

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27404846%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference